...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pediatric blood & cancer >Single‐agent bevacizumab in the treatment of recurrent or refractory pediatric low‐grade glioma: A single institutional experience
【24h】

Single‐agent bevacizumab in the treatment of recurrent or refractory pediatric low‐grade glioma: A single institutional experience

机译：单孕贝伐单抗治疗复发性或难治性儿科低级胶质瘤：单一的制度经验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Introduction Bevacizumab‐based therapy has been demonstrated to be effective in the treatment of refractory or recurrent pediatric low‐grade glioma (LGG); however its efficacy as a single agent is less understood. Methods We report our experience with single‐agent bevacizumab for the treatment of recurrent or refractory LGG treated with either standard 2?week dosing (10?mg/kg/dose every 2?weeks) or with a standard 2?week dosing followed by an increased interval dosing (10?mg/kg/dose every 4?weeks). Results From 2012 to 2017, 15 patients (five males and 10 females) with recurrent/refractory LGG (nine suprasellar, three thalamic, two brainstem, and one intramedullary spinal cord) were treated with a total of 156 doses of bevacizumab (115 every 2?week dosing, 41 every 4?week dosing, median 10 doses). Patients were refractory to a median of one nonsurgical therapy (range 0–3) prior to treatment with bevacizumab. Twelve of 15 demonstrated radiographic response (three complete, nine partial, and three stable disease). Significant clinical responses including improved visual fields (four), cranial neuropathy (three3), strength (seven), and gait (two) were observed. Bevacizumab was discontinued in 12 patients (resolution, one; disease stability, seven; progression, two; toxicity, one; and other, one) and three patients continue to receive monthly bevacizumab. Eleven patients eventually had radiographic progression (median 5 months, range 0.5–31) without clinical progression, and four of five receiving bevacizumab rechallenge had lpartial response. Conclusion Single‐agent bevacizumab is efficacious in the management of recurrent or refractory pediatric LGG with radiographic and clinical responses similar to those reported for bevacizumab‐based therapies.
机译：摘要介绍贝伐单抗的疗法已被证明在治疗难治性或复发性儿科低级胶质瘤（LGG）的治疗方面是有效的;然而，它作为单一代理的效果较少理解。方法我们向使用单颗粒Bevacizumab报告我们用标准2？周给药（每2个？周）或标准2？周给药后处理的复发性或难治性LGG的经验增加间隔给药（每4次10？mg / kg /剂量每4〜30℃）。结果2012年至2017年，15名患者（五名患者和10名女性），其经常性/难治性LGG（九个宿，三个丘脑，两个脑干和一个髓内脊髓），共有156剂Bevacizumab（每2次） ？周给药，41每4？周给药，中位数10剂）。在用Bevacizumab治疗之前，患者在一个非静脉治疗（范围0-3）中的中位数是难治的。十二例公证射线响应（三种完整，九个部分和三种稳定疾病）。观察到显着的临床反应，包括改进的视野（四），颅神经病变（三个），强度（7）和步态（两种）。 Bevacizumab在12名患者中停产（分辨率，一个;疾病稳定性，七;进展，两个;毒性，一个;一个）和三名患者继续接受每月贝伐单抗。 11名患者最终在没有临床进展的情况下进行了射线照相进展（中位数5个月，范围0.5-31），并且五种接受贝伐单抗重组中的四种具有液态反应。结论单孕叶蜡木制在与映射和临床反应类似于据报道的基于贝伐单抗的疗法的临床反应，有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号